Icagen, Inc. and Pfizer have extended their worldwide collaboration and licensing agreement aimed at discovering, developing and commercializing compounds as new potential treatments for pain and related disorders. For the past two years, the two companies have partnered to identify compounds that target three specific ion channels. The ion channel targets are sodium channels, which are important in the generation of electrical signals in nerve fibers that mediate the initiation, transmission...